

# Enzymatic Therapy

NATURAL MEDICINES®

October 12, 2003

8685 02 SEC -1 P1:49

NOV - 5 2003

Mr. Robert Moore  
Office of Nutritional Products, Labeling &  
Dietary Supplements, HFS 811  
Food and Drug Administration  
5100 Paint Branch Parkway  
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>COMPANY</u>	<u>PRODUCT NAME</u>	<u>DIETARY INGREDIENTS</u>	<u>STATEMENTS</u>
Enzymatic Therapy, Inc.	GS-500™	Chloride, Sodium, Glucosamine Sulfate	One packet, mixed once a day with water or other beverage, helps to maintain healthy joints.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.



By: \_\_\_\_\_


Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 10/12/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,



Michael P. Devereux  
Chief Financial Office

975 0162

LET 13247

GS-500 8e

# Enzymatic Therapy

NATURAL MEDICINES®

October 13, 2003

Mr. Robert Moore  
Office of Nutritional Products, Labeling &  
Dietary Supplements, HFS 811  
Food and Drug Administration  
5100 Paint Branch Parkway  
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>COMPANY</u>	<u>PRODUCT NAME</u>	<u>DIETARY INGREDIENTS</u>	<u>STATEMENTS</u>
Enzymatic Therapy, Inc.	GS-500™	Chloride, Sodium, Glucosamine Sulfate	To date, more than 20 clinical studies using glucosamine sulfate have been reported, with nearly 3,000 patients receiving either glucosamine sulfate or placebo. These studies show a favorable response to glucosamine sulfate vs. placebo in supporting healthy joint function.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 


Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 10/13/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,



Michael P. Devereux  
Chief Financial Office

GS-500 9e

825 Challenger Drive  
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com